EP4323350A1 — Isoindolinone compounds

USPTO Abstract

Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of Formula (I), wherein X 1 is selected from the group consisting of linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X 1 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , CMeF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, NH 2 , C 1-4 alkoxy and C 1-4 alkylhydroxy; X 2 is selected from the group consisting of H, C 3-6 cycloalkyl, C 6 -10 aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X 2 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of linear or branched C 1-6 alkyl, -C 1-4 alkoxy, NH 2 , NMe 2 , halogen, CF 3 , CHF 2 , CMeF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , OCHF 2 , and C 1-4 alkylhydroxy; Y is selected from the group consisting of linear or branched C 1-6 alkyl, -C 1-4 alkoxy, -CN, halogen, CF 3, CHF 2 , CMeF 2 , OCF 3 , and OCHF 2 ; L 1 is linear or branched C 1-6 alkyl; L 2 is selected from a covalent bond, and linear or branched C 1-6 alkyl; and L 3 is selected from the group consisting of a covalent bond, linear or branched C 1-6 alkyl, -O-, and -C 1-4 alkoxy. Disclosed herein is also their use as modulators of cereblon, methods of preparation of these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, especially humans.